HUDSON, NY--(Marketwire - February 03, 2010) - Taconic today announces the establishment of a
specialized breeding facility in Edinburgh. The facility will be used for
the development and production of the most technologically advanced models
available to scientists today, while creating new jobs locally. The site is
intended as the first stage in establishing a strong Taconic presence in
Since 2005, TaconicArtemis GmbH, a German-based subsidiary of Taconic, has
been working with its Scottish partner CXR Biosciences Ltd (Dundee,
Scotland) to deliver novel, commercially viable, models that are more
predictive of the pharmacokinetic and toxicological effects of candidate
drug compounds and their metabolites in the human body. This work is
supported by the Intermediary Technology Institute, dedicated to life
sciences (ITI Life Sciences), which was formed as part of a flagship
programme by Scottish Enterprise to help Scotland turn its world-class
research in life sciences into commercial successes.
Based on the success of the programme, TaconicArtemis and CXR Biosciences
have signed three commercial licences with ITI Life Sciences to allow them
to co-commercialise a range of drug screening models and services developed
using these new technologies More than 40 transgenic strains generated in
this program are now included in the companies' transADMET programme.
Current preclinical models can be poorly predictive of absorption,
distribution, metabolism, excretion and toxicology (ADMET) in man. This
inability to translate animal results to man is driven by profound
interspecies differences in the levels and functions of proteins involved
in ADMET, and is a major reason for development failure in the
pharmaceutical and chemical industries. The transADMET programme offers an
improved preclinical means of predicting human ADMET response. In each
model, key genes have been knocked out or replaced with their human
counterparts -- improving the pharmacokinetic and safety assessment of drug
candidates by yielding research results that are more predictive of man.
"Together, Taconic and CXR Biosciences are empowering investigators with
sophisticated new tools that can revolutionize drug discovery and provide a
strong competitive advantage," said Todd Little, President and CEO,
Taconic. "Our new transADMET models will enable researchers to advance drug
discovery more effectively, minimize the odds of late-stage failure and
improve time-to-market with viable new drug therapies."
"The ground-breaking transADMET models will transform pharmaceutical
research and chemical safety assessment by allowing scientists to more
closely reflect the human situation in preclinical studies, thereby
reducing the likelihood of problems occurring later in clinical trials,"
said Tom Shepherd, CEO, CXR Biosciences. "The decision by Taconic to locate
here to develop this platform with CXR will establish a unique world
leading translational research capability in Scotland."
Rhona Allison, senior director of life sciences, Scottish Enterprise, said:
"Despite difficult economic conditions Scotland's life sciences sector has
continued to grow and develop in recent years. Taconic's investment in
this specialized facility is a strong indication of continued confidence in
Scotland as an excellent location for life sciences."
The transADMET program is the culmination of a five-year, $13 million
effort funded by ITI Life Sciences. CXR Biosciences validated the
transADMET models, while TaconicArtemis served as the primary generator of
the new models.
Taconic Farms, Inc. was founded in 1952 as a family-owned business in New
York's Hudson River Valley. Since then, the company has become one of the
largest laboratory rodent providers in the world with a reputation for
consistently producing high quality, well-defined rats and mice. Taconic's
expertise in the custom design and generation of genetically modified mice,
mouse and rat breeding, barrier systems, genetics and animal health
supports researchers focused on drug development using in vivo models.
Taconic has six breeding facilities and three service laboratories in the
USA and Europe, a staff of over 1,000, and a commitment to technological
innovation. Additional information about Taconic is available through its
corporate website, www.taconic.com.
About CXR Biosciences
Founded in 2001, CXR Biosciences has used its collaborative approach,
proprietary models and cutting edge expertise to help customers of all
sizes solve issues relating to the selection of drug candidates or safety
of compounds. CXR develops preclinical technology platforms that are more
predictive of drug response in man, as well as offering tailored
preclinical services in the areas of drug development and investigative
toxicology. The company has business relationships with over sixty
customers and collaborators, including pharmaceutical companies, chemical
companies, biotechnology companies, leading universities and research
institutions. CXR Biosciences Ltd. is located in Dundee, Scotland. More
information can be found at www.cxrbiosciences.com.